{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T08:04:04Z","timestamp":1793865844745,"version":"4.6.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,10,15]],"date-time":"2014-10-15T00:00:00Z","timestamp":1413331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2014,10,15]],"date-time":"2014-10-15T00:00:00Z","timestamp":1413331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>Calcium pyrophosphate deposition (CPPD) may cause severe arthropathy, major joint destruction and treatment options are limited. The aim of this study was to test the therapeutic efficacy of methotrexate (MTX) in chronic or recurrent CPPD arthropathy.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>Patients with CPPD arthropathy were randomized to receive either weekly subcutaneous injections of 15 mg\/week of MTX or placebo (PBO) for three months, in a double-blind, crossover randomized controlled trial. Inclusion criteria comprised definite CPPD disease, recurrent arthritis or persistent polyarthritis, and an insufficient response to NSAIDs, glucocorticoids or colchicine. The primary outcome was an improvement in the disease activity scores based on 44 joints (DAS44). The analysis was performed on an intent-to-treat basis.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>We randomized 26 patients, and compared 25 treatment periods on MTX with 21 treatment periods on PBO. Baseline characteristics were balanced between the groups. The evolution of the DAS44 was not statistically significantly different between groups (median DAS44 decreased by \u22120.08 on MTX versus \u22120.13 on PBO, after three months, <jats:italic>P<\/jats:italic> = 0.44). Furthermore, pain levels remained stable in both groups (median change in VAS Pain \u22121 unit on MTX and 0 on PBO, <jats:italic>P<\/jats:italic> = 0.43), and none of the secondary outcomes was significantly different between the two groups. Minor adverse events (AE) did not differ in frequency between the groups, but the only serious AE occurred on MTX (bicytopenia).<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>The results of this trial with MTX in this older population with chronic or recurrent CPPD arthropathy suggest no strong effect of MTX on disease activity.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Trial registration<\/jats:title>\n                        <jats:p>EudraCT No: 2007-003479-37. Registered 26 April 2008<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/s13075-014-0458-4","type":"journal-article","created":{"date-parts":[[2014,10,13]],"date-time":"2014-10-13T14:37:07Z","timestamp":1413211027000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial"],"prefix":"10.1186","volume":"16","author":[{"given":"Axel","family":"Finckh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine M","family":"Mc Carthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Madigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Van Linthoudt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Rappoport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Blumhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Kyburz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Andre","family":"Guerne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,10,15]]},"reference":[{"key":"458_CR1","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1136\/ard.2010.139105","volume":"70","author":"W Zhang","year":"2011","unstructured":"Zhang W, Doherty M, Bardin T, Barskova V, Guerne PA, Jansen TL, Leeb BF, Perez-Ruiz F, Pimentao J, Punzi L, Richette P, Sivera F, Uhlig T, Watt I, Pascual E: European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis. 2011, 70: 563-570. 10.1136\/ard.2010.139105.","journal-title":"Ann Rheum Dis"},{"key":"458_CR2","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/ard.2010.139360","volume":"70","author":"W Zhang","year":"2011","unstructured":"Zhang W, Doherty M, Pascual E, Barskova V, Guerne PA, Jansen TL, Leeb BF, Perez-Ruiz F, Pimentao J, Punzi L, Richette P, Sivera F, Uhlig T, Watt I, Bardin T: EULAR recommendations for calcium pyrophosphate deposition. Part II: management. Ann Rheum Dis. 2011, 70: 571-575. 10.1136\/ard.2010.139360.","journal-title":"Ann Rheum Dis"},{"key":"458_CR3","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.jbspin.2009.01.001","volume":"76","author":"N Announ","year":"2009","unstructured":"Announ N, Palmer G, Guerne PA, Gabay C: Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure. Joint Bone Spine. 2009, 76: 424-426. 10.1016\/j.jbspin.2009.01.001.","journal-title":"Joint Bone Spine"},{"key":"458_CR4","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/RHU.0b013e31826149a2","volume":"18","author":"AP Diamantopoulos","year":"2012","unstructured":"Diamantopoulos AP, Brodin C, Hetland H, Haugeberg G: Interleukin 1beta blockade improves signs and symptoms of chronic calcium pyrophosphate crystal arthritis resistant to treatment. J Clin Rheumatol. 2012, 18: 310-311. 10.1097\/RHU.0b013e31826149a2.","journal-title":"J Clin Rheumatol"},{"key":"458_CR5","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nrrheum.2010.5","volume":"6","author":"ES Chan","year":"2010","unstructured":"Chan ES, Cronstein BN: Methotrexate\u2013how does it really work?. Nat Rev Rheumatol. 2010, 6: 175-178. 10.1038\/nrrheum.2010.5.","journal-title":"Nat Rev Rheumatol"},{"key":"458_CR6","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/art.22389","volume":"56","author":"A Chollet-Janin","year":"2007","unstructured":"Chollet-Janin A, Finckh A, Dudler J, Guerne PA: Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis. Arthritis Rheum. 2007, 56: 688-692. 10.1002\/art.22389.","journal-title":"Arthritis Rheum"},{"key":"458_CR7","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/RHU.0b013e3182611471","volume":"18","author":"M Andres","year":"2012","unstructured":"Andres M, Sivera F, Pascual E: Methotrexate is an option for patients with refractory calcium pyrophosphate crystal arthritis. J Clin Rheumatol. 2012, 18: 234-236. 10.1097\/RHU.0b013e3182611471.","journal-title":"J Clin Rheumatol"},{"key":"458_CR8","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1002\/art.23552","volume":"58","author":"TH Doan","year":"2008","unstructured":"Doan TH, Chevalier X, Leparc JM, Richette P, Bardin T, Forestier R: Premature enthusiasm for the use of methotrexate for refractory chondrocalcinosis: comment on the article by Chollet-Janin et al. Arthritis Rheum. 2008, 58: 2210-2211. 10.1002\/art.23552.","journal-title":"Arthritis Rheum"},{"key":"458_CR9","doi-asserted-by":"publisher","first-page":"738","DOI":"10.7326\/0003-4819-56-5-738","volume":"56","author":"NN Kohn","year":"1962","unstructured":"Kohn NN, Hughes RE, Mc CD, Faires JS: The significance of calcium phosphate crystals in the synovial fluid of arthritic patients: the \u201cpseudogout syndrome\u201d. II. Identification of crystals. Ann Intern Med. 1962, 56: 738-745. 10.7326\/0003-4819-56-5-738.","journal-title":"Ann Intern Med"},{"key":"458_CR10","unstructured":"Efficacy of methotrexate on chronic calcium pyrophosphate dihydrate deposition disease (chondrocalcinosis)., [http:\/\/www.controlled-trials.com\/ISRCTN79343755]"},{"key":"458_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/art.23144","volume":"58","author":"J Braun","year":"2008","unstructured":"Braun J, Kastner P, Flaxenberg P, Wahrisch J, Hanke P, Demary W, von Hinuber U, Rockwitz K, Heitz W, Pichlmeier U, Guimbal-Schmolck C, Brandt A: Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008, 58: 73-81. 10.1002\/art.23144.","journal-title":"Arthritis Rheum"},{"key":"458_CR12","unstructured":"Fransen J, van Riel PL: The Disease Activity Score and the EULAR response criteria.Clin Exp Rheumatol 2005, Suppl 39:S93\u2013S99.,"},{"key":"458_CR13","first-page":"2452","volume":"32","author":"HR Schumacher Jr","year":"2005","unstructured":"Schumacher HR, Edwards LN, Perez-Ruiz F, Becker M, Chen LX, Furst DE, Joseph-Ridge N, Schlesinger N, Horowitz Z, Saag K, Boice JA, Yamanaka H, Group OSI: Outcome measures for acute and chronic gout. J Rheumatol. 2005, 32: 2452-2455.","journal-title":"J Rheumatol"},{"key":"458_CR14","unstructured":"Soci\u00e9t\u00e9 Suisse de Rhumatologie\/Schweizer Geselschaft f\u00fcr Rheumatologie: Recommendations pour les traitements de base de Methotrexate. 2004."},{"key":"458_CR15","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1002\/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7","volume":"44","author":"AE van Ede","year":"2001","unstructured":"van Ede AE, Laan RF, Rood MJ, Huizinga TW, van de Laar MA, van Denderen CJ, Westgeest TA, Romme TC, de Rooij DJ, Jacobs MJ, de Boo TM, van der Wilt GJ, Severens JL, Hartman M, Krabbe PF, Dijkmans BA, Breedveld FC, van de Putte LB: Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2001, 44: 1515-1524. 10.1002\/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7.","journal-title":"Arthritis Rheum"},{"key":"458_CR16","doi-asserted-by":"crossref","unstructured":"Jones B, Kenward MG: Design and Analysis of Cross-Over Trials. In: Monographs on Statistics and Applied Probability. Chapman and Hall; 1989.","DOI":"10.4324\/9780203009277"},{"key":"458_CR17","unstructured":"R Development Core Team: R: A language and environment for statistical computing.R Foundation for Statistical Computing: Vienna, Austria; 2008.,"},{"key":"458_CR18","first-page":"514","volume":"36","author":"Y Kawabe","year":"1996","unstructured":"Kawabe Y, Eguchi K, Tsuboi M, Kita M, Tsukada T, Takashima H, Mizokami A, Kawakami A, Matsuoka N, Migita K, Nagataki S: Untoward effects of low dose methotrexate therapy in rheumatoid arthritis. Ryumachi [Rheumatism]. 1996, 36: 514-521.","journal-title":"Ryumachi [Rheumatism]"},{"key":"458_CR19","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1177\/0961203313509295","volume":"22","author":"B Duxbury","year":"2013","unstructured":"Duxbury B, Combescure C, Chizzolini C: Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis. Lupus. 2013, 22: 1489-1503. 10.1177\/0961203313509295.","journal-title":"Lupus"},{"key":"458_CR20","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/01.bor.0000157042.19740.f4","volume":"17","author":"Y Zhang","year":"2005","unstructured":"Zhang Y, Brown MA: Genetic studies of chondrocalcinosis. Curr Opin Rheumatol. 2005, 17: 330-335. 10.1097\/01.bor.0000157042.19740.f4.","journal-title":"Curr Opin Rheumatol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-014-0458-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-014-0458-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-014-0458-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-014-0458-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T16:24:16Z","timestamp":1728923056000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-014-0458-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,15]]},"references-count":20,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,10]]}},"alternative-id":["458"],"URL":"https:\/\/doi.org\/10.1186\/s13075-014-0458-4","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,15]]},"assertion":[{"value":"24 March 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"458"}}